Atezolizumab After Progression With Prior Ici Treatment Shows No Benefit And Increases Toxicity

Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Improvement in RFS for atezolizumab plus bevacizumab vs active surveillance without compromising QoL

Outcomes with multikinase inhibitors after progression on first-line atezolizumab-bevacizumab in HCC

ASCO 2023: Highlights and analysis

Molecular Targeted Therapies for Advanced HCC

Icahn School of Medicine

Improving outcomes in ICI-associated acute kidney injury

Medicine Grand Rounds: Rheumatology 2/27/18

Emory Department of Medicine

Atezolizumab Injection Explained: Uses, Dosage, Mechanism, Side Effects & Advice | MediInsights

Hepatobiliary Cancers | Cases from the Community: Investigators Discuss Available Research Guidin...

Research To Practice

The role of immunohistochemistry in assessing ICI efficacy

Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC

PeerView Oncology

KCR22 Session Six: Clinical & Scientific Updates in Kidney Cancer

Challenges to Precision Medicine for Anti-Cancer Immunotherapy

Yale Cancer Center

YW2023: ‘’Immunotherapy Combinations for Advanced HCC‘’ - Lorenza Rimassa, MD

Fondazione Italiana Fegato - FIF ONLUS

ESMO 2020: Lung cancer latest

YW2023: "Immunotherapy for HCC: Challenges in Clinical Practice"

Fondazione Italiana Fegato - FIF ONLUS

Role of the Pulmonologist in the Early Detection & Management of Lung Cancer Treatment Complications

Kidney Cancer Conference Highlights from ASCO 2023

Dana-Farber Cancer Institute

Drs. Salem & Yarchoan discuss #HCC - https://bit.ly/3lz7kWZ

PeerView Oncology